Table2.Immunological,biological,hematological,andradiologicaldataandprofileofpatientswithrheumatoidarthritis(RA):Algiers(Algeria):2018-2019.
|
Data |
Outcome |
Unit/Category |
Total sample (n=59) |
ACPA - (n=33) |
ACPA + (n=26) |
p-value |
|
Immunological data and profile |
ACPA |
(U/ml) |
59±175 |
1±1 |
133±248 |
0.0034 * |
|
ANA cut-off (titer) |
≥1/160(%) |
161±238 |
128±161 |
202±308 |
0.2453 |
|
|
Rheumatoid factor (RF) |
(IU/ml) |
85±124 |
62±91 |
114±154 |
0.1122 |
|
|
RF subgroups |
Negative |
13 (22.0) |
2 (6.1) |
11 (42.3) |
0.009 * |
|
|
Positive |
46 (78.0) |
31 (93.9) |
15 (57.7) |
0.009 * |
||
|
RF levels |
Light |
22 (37.3) |
18 (54.5) |
4 (15.4) |
0.0020 * |
|
|
Moderate |
11 (18.6) |
9 (27.3) |
2 (7.7) |
0.0551 |
||
|
High |
7 (11.9) |
2 (6.1) |
5 (19.2) |
0.1225 |
||
|
Very high |
6 (10.2) |
2 (6.1) |
4 (15.4) |
0.2412 |
||
|
Biological data and profile |
ESR (1st hour) |
(mm) |
52±33 |
51±30 |
54±37 |
0.6831 |
|
C-reactive protein |
(mg/L) |
28±43 |
21±33 |
36±51 |
0.1640 |
|
|
High ESR |
(yes) |
15 (25.4) |
8 (24.2) |
7 (26.9) |
0.8130 |
|
|
High C-reactive protein |
(yes) |
28 (47.5) |
13 (39.4) |
15 (57.7) |
0.1623 |
|
|
Biological inflammatory syndrome |
(yes) |
48 (81.4) |
25 (75.8) |
23 (88.5) |
0.2204 |
|
|
Hemoglobin |
(g/L) |
12±2 |
12±2 |
12±2 |
0.9362 |
|
|
Hematological data and profile |
White blood cells |
(/mm3) |
7810±2682 |
7953±2551 |
7627±2881 |
0.6469 |
|
Polynuclear neutrophils |
(/mm3) |
4657±1916 |
4796±1939 |
4481±1910 |
0.5352 |
|
|
Polynuclear eosinophils |
(/mm3) |
258±543 |
189±139 |
346±804 |
0.2746 |
|
|
Lymphocytes |
(/mm3) |
2272±948 |
2304±846 |
2231±1080 |
0.7733 |
|
|
Monocytes |
(/mm3) |
623±244 |
665±257 |
570±219 |
0.1373 |
|
|
Anemia |
(yes) |
22 (37.3) |
13 (39.4) |
9 (34.6) |
0.7050 |
|
|
Leukocytosis |
(yes) |
8 (13.6) |
5 (15.2) |
3 (11.5) |
0.6803 |
|
|
Bronchiectasis |
(yes) |
16 (27.1) |
7 (21.2) |
9 (34.6) |
0.2503 |
|
|
Radiological data |
Bronchial wall thickening |
(yes) |
2 (3.4) |
0 (0.0) |
2 (7.7) |
0.1048 |
|
Thickened septal/non-septal lines |
(yes) |
45 (76.3) |
23 (69.7) |
12 (46.2) |
0.0681 |
|
|
Interstitial lung disease |
(yes) |
43 (72.9) |
27 (81.8) |
16 (61.5) |
0.0817 |
|
|
Nonspecific interstitial pneumonia |
(yes) |
32 (54.2) |
19 (57.6) |
13 (50.0) |
0.5607 |
|
|
Bronchiolitis |
(yes) |
18 (30.5) |
8 (24.2) |
10 (38.5) |
0.2362 |
|
|
Ground glass attenuation |
(yes) |
34 (57.6) |
20 (60.6) |
14 (53.8) |
0.5998 |
|
|
Usual interstitial pneumonia |
(yes) |
9 (15.3) |
6 (18.2) |
3 (11.5) |
0.4772 |
|
|
Micro nodule |
(yes) |
35 (59.3) |
19 (57.6) |
16 (61.5) |
0.7621 |
|
|
Air space consolidation |
(yes) |
32 (54.2) |
19 (57.6) |
13 (50.0) |
0.5607 |
ACPA: Anti-Citrullinated Peptides Antibodies. ANA: Anti-Nuclear Antibody. ESR: Erythrocyte Sedimentation Rate. Quantitative and categorical data were mean±SD and number (%), respectively. *p-value < 0.05: 2 sided Chi-square test (comparison of categorical data between the 2 groups) Student's T test (comparison of quantitative data between the 2 groups).